Publications by authors named "Brian Piepenbroek"
Background: Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits.
View Article and Find Full Text PDFArticle Synopsis
- Haploidentical stem cell transplantation (haplo-SCT) helps children with a genetic problem that affects their bone marrow when they can’t find a matching donor.
- A study looked at 162 patients and found that the best type of T-cell removal, called TCRαβ/CD19 depletion, led to better survival rates and fewer serious side effects.
- Overall, the study shows that haplo-SCT is a safe option and that the TCRαβ/CD19 method could give kids with these conditions a better chance to live without severe complications.
Purpose: To understand the current practice in relation to the management of topical therapy for cutaneous chronic Graft versus Host Disease (ccGvHD) and access to extracorporeal photopheresis (ECP) within European allogeneic haematopoietic cell transplantation centres by a survey of nurses.
Method: This was a multicentre cross-national study at eligible European Blood and Marrow Transplant centres. Eligibility required more than 30% of treated patients having allogeneic haematopoietic cell transplant.
Although CMML since long has been separated from MDS, many studies continue to evaluate the outcomes of both diseases after hematopoietic cell transplantation (allo-HCT) together. Data evaluating outcomes of a large CMML cohort after allo-HCT compared to MDS are limited. We aim to compare outcomes of CMML to MDS patients who underwent allo-HCT between 2010 and 2018.
View Article and Find Full Text PDFArticle Synopsis
- Androgens have historically been used to treat bone marrow failure (BMF) syndromes, but there's limited prospective data on their effectiveness and safety in these conditions.
- A retrospective analysis involving 274 BMF patients from various European centers showed low remission rates after androgen treatment, with varying survival outcomes based on the type of BMF.
- The study highlights the potential for androgens to be a manageable treatment option with minimal severe side effects, supporting their continued use and setting the groundwork for future clinical recommendations.